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Epidemiological data on hepatitis delta virus
(HDV) infection in Belgium are lacking. A multi-
center questionnaire-based registry on HDV in-
fection was collated between March 1, 2008 and
February 28, 2009. It consisted of patients co-
infected with hepatitis B virus (HBV) and HDV.
The data samples were compared to those of a
concurrent registry on HBV infection. Prospec-
tive data of patients with HBV–HDV coinfection
were collected. Active HBV replication is defined
as HBeAg positivity or HBV DNA > 2,000 IU/ml.
Forty-four patients from 15 centers were regis-
tered. A comparison of 29 patients infected with
HDV (registered in the concurrent HBV registry)
was made against 785 HBV mono-infected pa-
tients. The seroprevalence of patients coinfected
with HBV and HDV in Belgium is reported to be
3.7% (29/785), consisting solely of the HBV–HDV
coinfected patients in the HBV registry. This rises
to 5.5% (44/800) if all patients infected with HDV
from the two registries combined are included.
The patients coinfected with HBV and HDV had
higher (P < 0.05) ALT values andmore advanced
liver disease (Metavir score F2), but had less
active HBV replication and lower HBV DNA titers
when compared with the patients infected only
with HBV. Additionally, the majority of HBV–
HDV coinfected patient was male, and 13.6% (6/
44) of the patients that were coinfected HBV and
HDV were also infected with HCV. In conclusion,
this study provided much needed epidemiologi-
cal data on the current state of HDV infection
in Belgium. J. Med. Virol. 85:1513–1517,
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INTRODUCTION
Hepatitis delta virus (HDV) is an RNA virus
discovered by Rizzetto et al. [1977]. HDV requires the
hepatitis B virus (HBV) surface protein (HBsAg) to
replicate and a high rate of HBV infection to achieve
endemicity. This was determined to be the case at
the time of HDV discovery in the Mediterranean
[Rizzetto et al., 1977] and other geographical areas.
Worldwide vaccination efforts to control chronic
infection with HBV [Chang, 2003], the companion
virus of HDV, and reports of declining anti-HDV
antibody prevalence in a large group of HBsAg
positive patients in Italy throughout the 1990s [Cian-
cio and Rizzetto, 2002], have led to the common belief
that HDV infection was vanishing and subsequently
reduced interest in the virus among health
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professionals. However, renewed interest emerged in
the mid-2000s when Wedemeyer et al. [2007] showed
a sustained prevalence of HDV in Central Europe.
Further reports from Cross et al. [2008] and Le Gal
et al. [2007] also showed similar findings in the UK
and France, respectively. Both reports suggested that
migration of individuals was an important factor in
the persistence of chronic hepatitis delta infection.
There is currently a lack of epidemiological data on
HBV–HDV coinfection in Belgium. However, the
discovery of sustained HDV in geographically close
areas such as central Europe, the UK, and France,
and the established severity of HBV–HDV super
infection in patients [Yurdaydın et al., 2010] necessi-
tate a need for an epidemiological survey of HDV in
Belgium. Therefore, the aim of this study was to
provide epidemiological data on the prevalence and
clinical characteristics of HDV infection in patients
chronically infected with HBV in Belgium.
METHODS
Survey Design and Participants
A 1-year prospective, questionnaire-based registry
was performed from March 1st, 2008 until
February 28th, 2009 under the aegis of the Belgian
Association for the Study of the Liver (BASL). Partici-
pating in the study were gastroenterologists and
hepatologists from different Belgian University hospi-
tals and large non-university hospitals. The question-
naires were standardized forms, with inquiries
towards basic characteristics of the patients, HBV,
HCV, and HIV status, liver disease parameters, histo-
logical parameters, and treatment modalities. Hepatic
histological activity (A) and liver fibrosis (F) were
measured using the Metavir score (A0-3, F0-4) [Bed-
ossa and Poynard, 1996]. Active HBV replication was
defined as when a patient was positive for HBeAg, or
when HBV DNA was >2,000 IU/ml if HBeAg was
determined to be negative. All questionnaires were
accompanied by informed consent forms. The question-
naires were sent out to participating hepatologists and
gastroenterologists throughout Belgium.
This study was undertaken in compliance with the
relevant laws and institutional guidelines and in
accordance with the ethical standards of the Declara-
tion of Helsinki. The registration study was approved
by the Committee of Bio-ethics of the Antwerp
University Hospital. A signed informed consent form
was obtained from all included patients.
Data from this registration study were compared to
data from the concurrent Belgian HBsAg registry from
Deltenre et al. [2012], which was conducted in the
same timeframe and was made with data from approx-
imately the same participating centers in Belgium.
Serological Analysis
Patient samples were sent to the Belgian Scientific
Institute of Public Health (Brussels, Belgium), the St.
Luc, UCL University Hospital (Brussels, Belgium) or
the St. Pierre University Hospital (Brussels,
Belgium) for HDV serologic testing. HDV serology
was performed in all laboratories by detection of total
anti-HDV antibodies in serum using the commercial-
ly available ETI-AB-DELTAK-2 enzyme immunoas-
say (DiaSorin S.p.A. Turin, Italy), in accordance to
the instructions of the manufacturer.
Statistical Analysis
Data were tabulated in SPSS [version 19, IBM Inc.,
2010]. Statistical analysis was performed using the
Mann–Whitney U-test for continuous variables and
the Chi-square test for categorical variables. P < 0.05
was considered to be statistically significant.
RESULTS
In total, 15 centers participated in the study.
Forty-four patients were registered in the HDV
registry as having HBV–HDV coinfection. Half of the
patients (22/44) were Caucasians, 34.1% (14/44) were
Black Africans, 9.1% (4/44) were from Asia and 6.8%
(3/44) were from another ethnic origin. The risk
factors for HBV–HDV coinfection in these patients
were uncertain or unknown in the majority of the
cases (56.8%, 25/44); however, in a small number of
cases, intravenous drug use (11.4%, 5/44), and sexual
contact (13.6%, 6/44) were identified as important
risk factors. Of patients coinfected with HBV and
HDV, 29.5% (13/44) tested HBeAg positive, 13.6% (6/
44) had a HBV DNA level of 2,000 IU/L and 15.9%
(7/44) had HBV DNA level above that. Most of the
patients were untreated, only 16 were reported to
have been treated with interferon or pegylated inter-
feron and two patients underwent liver transplanta-
tion. The survey also examined HCV and HIV
infection in all the patients with HBV–HDV coinfec-
tion and found that 13.6% (6/44) were also infected
with HCV, but none of the patients were infected
with HIV.
When comparing data from the concurrent HBsAg
registry compiled by Deltenre et al. [2012], amongst
the 785 patients in that registry tested for HDV
antibodies, 29 patients were registered as having
HBV–HDV coinfection. Fifteen more patients were
entered in the HDV registry in the same centers.
During the concurrent time period, these patients
were not formally entered in the aforementioned
HBV registry. Thus, the suspected seroprevalence in
Belgium of HBV–HDV coinfection is 3.7–5.5% (29/
785–44/800).
Numerous parameters were compared between (a)
the patients infected with only HBV and (b) the
patients infected with HBV and HDV (Table I).
Patients coinfected with HBV and HDV had signifi-
cantly higher ALT values. These patients presented
more advanced liver disease according to the Metavir
score, with significantly less HBV active replication
and lower HBV DNA titers when compared with the
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patients infected only with HBV from the HBsAg
registry.
DISCUSSION
The large volume of research on viral hepatitis, in
particular hepatitis B and more recently hepatitis C,
is in stark contrast with the relative lack of interest
in hepatitis delta. Therefore, this report aims to
provide epidemiological data, including prevalence, of
HBV–HDV coinfection in Belgium by compiling a
HDV registry and comparing it with the concurrent
HBsAg registry.
In the HDV registry, 44 individuals coinfected with
HBV and HDV were registered over the course of
1 year. However, the concurrent HBsAg registry by
Deltenre et al. [2012] found only 29 patients coin-
fected with HDV. This discrepancy between these
two registries illustrates the inherent inaccuracy of
cross-sectional registration which could be caused by
the fact that the population of patients examined in
both registries are not the same even though both
registries compiled data from largely the same cen-
ters and time period (March 2008–March 2009) in
Belgium. Despite this, the reported suspected range
of seroprevalence concurs with data found in the
literature and may be a better reflection of the actual
seroprevalence of HBV–HDV coinfection in Belgium.
A large proportion of patients coinfected with HBV
and HDV originated from outside Western Europe
(Table I). Although 50% (22/44) of the patients were
of Caucasian descent, only eight were confirmed from
Belgian descent. Four patients were from Italy, and
the remaining 10 were from Eastern Europe. Previ-
ous studies from the UK [Cross et al., 2008],
Germany [Erhardt et al., 2010], and France [Le Gal
et al., 2007] also reported a large proportion of HBV
and HDV infected patients originating from outside
Western Europe. Cross et al. [2008] studied the
prevalence of hepatitis delta in the south of London
and reported a seroprevalence of 8.5%. This percent-
age was lower (7.1%) when only UK residents were
included. A significant portion of subjects were from
regions of high HBV endemicity (28.1% from South
and Eastern Europe, 28.6% from Africa). A retrospec-
tive study, by Erhardt et al. [2010], in Germany
where the seroprevalence of 1,307 HBsAg carriers
was investigated for HBV–HDV coinfection over the
course of two decades (1989–2008) showed that 46.2%
of subjects were immigrants from the former Soviet
Union and 17.9% were from Africa. In France, an
analysis of 617 patients with a novel infection with
HDV from 2001 to 2006 showed a rising proportion of
patients from Africa [Le Gal et al., 2007].
The Asia-Pacific region, an area known to be
endemic for hepatitis B, interestingly has shown a
decline in the prevalence of hepatitis delta [reviewed
by Abbas et al., 2010]; most of the data incorporated
in this review involved studies from the late 1990s.
Recent studies from Pakistan and South Korea have
revealed new and contrasting epidemiological data on
HDV prevalence. Studies in Pakistan [Khan et al.,
2011; Mumtaz et al., 2011] showed a high prevalence
of HDV; Mumtaz et al. [2011] reported HBV–HDV
coinfection at 35.2%. In addition, Khan et al. [2011]
found that within Pakistan, there are significant
regional differences in HDV prevalence; the Sindh
area reports HBV–HDV coinfection at 67% while the
Khyber Pakhtoonkhaw and Punjab areas reported
6% and 4%, respectively. In contrast to Pakistan,
HBV–HDV coinfection in South Korea is reported to
be very low at 0.32% (3/940 patients) [Kim et al.,
2011].
Interestingly, there are certain subpopulations in
the general population that maintain a high HDV
prevalence. These tend to be in isolated populations
that also have high hepatitis B prevalence. For
example, in Greenland, there was an outbreak of
hepatitis delta amongst children and adolescents
20 years old and younger [Borresen et al., 2010]. In
TABLE I. Comparison of Variables Between Patients Infected Only With Hepatitis B Virus (HBV) and Patients
Co-Infected With HBV and Hepatitis Delta Virus (HDV)
Variable HBV patientsa HBV–HDV patientsa Statistical significance
Continuousb
Age 40.00(median) 38.00(median) P > 0.05
HBV viral load (lU/ml) 726.00(median) 100.00(median) P ¼ 0.028
Categoricalc
Gender: male 67.90% (514/757) 79.31% (23/29) P ¼ 0.195
Race: non-Caucasian 48.40% (364/752) 48.28% (14/29) P > 0.05
HBV active replicationd 49.56% (336/678) 23.08% (6/26) P ¼ 0.008
Anti-HCV antibody positivity 2.55% (19/746) 7.14% (2/28) P ¼ 0.142
Anti-HIV antibody positivity 1.56% (11/707) 0% (0/28) P > 0.05
ALT > 2N 13.66% (103/754) 34.48% (10/29) P ¼ 0.002
Fibrosis F3F4e 36.46% (144/395) 76.19% (16/21) P ¼ 0.000
aTotal patients differ due to missing data.
bAnalysis with Mann–Whitney U-test.
cAnalysis with cross tabulation and Chi-square test.
dHBV active replication: HBeAg positive or HBV DNA >2,000 lU/ml if HBeAg negative.
eMetavir fibrosis score F3 or F4 [Bedossa and Poynard, 1996].
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2006, 27% of the population in a small settlement in
the west of Greenland was HBsAg positive, and 46%
were 20 years old or younger; however, the percent-
age of HDV prevalence in that age group increased
1 year later where 68% of them were found to be
anti-HDV IgG positive [Borresen et al., 2010]. A
similar pattern of high HDV prevalence in isolated
populations is also found in the Western Amazonian
Basin [Viana et al., 2005]. Other hyper endemic
regions like the southeast of Turkey also report a
high prevalence of HBV–HDV coinfection (27%) [De-
g˘ertekin et al., 2008].
Serological analysis in our study showed that
patient coinfected with HBV and HDV have higher
ALT values and generally higher fibrosis scores
(Table I); this finding supports the fact that HBV–
HDV coinfection tends to cause more severe liver
disease [Yurdaydın et al., 2010]. However, to under-
stand the long-term effects of HBV–HDV coinfection
on patients, longer follow-up of the clinical course
may be needed. One study by Romeo et al. [2009]
followed 300 patients with persistent hepatitis Delta
infection and found an annual cirrhosis rate of 4%
and HCC rate of 2.8%. Within that study, the authors
state that active HDV replication is the only predic-
tor for liver related mortality.
Our study also demonstrated that a significant
minority of patients retain active HBV infection but,
at the same time, there are generally lower HBV
DNA levels in patients coinfected with HBV and
HDV. This observation is supported by previous
findings [Jardi et al., 2001; Sakugawa et al., 2001;
Erhardt et al., 2010]. Further study may be required
to explain this phenomenon, for example by testing
quantitative HBsAg and covalently closed circular
DNA (cccDNA). Shih et al. [2008] show a correlation
between HBsAg levels and HDV RNA in HBV–HDV
coinfected patients with undetectable levels of HBV
DNA, but not in patients with detectable HBV DNA
levels. Moreover, HBV DNA levels were not correlat-
ed with HDV RNA levels. This suggests HDV replica-
tion is independent from HBV replication and that it
competes with HBV for HBsAg (which both viruses
require to construct infective virions). Interestingly,
these findings were only partly confirmed in a study
by Heidrich et al. [2009]: 258 patients coinfected with
HDV and HBV were compared to 2,083 patients
infected with HBV alone. Lower HBV DNA levels
were detected in the coinfected patients and no
correlation between HDV RNA and HBV DNA levels
was found. In contrast, no difference in HBsAg level
was found between coinfected patients and monoin-
fected patients.
A study by Pollicino et al. [2011] investigated the
intrahepatic interactions of HBV and HDV, elucidat-
ing how HDV suppresses HBV. They found that,
during a HBV–HDV coinfection, there is a decrease
in HBV DNA and pregenomic RNA, but a persistence
of HBsAg and preS/S RNA. Furthermore, HBV
genomes with large deletions in the basal-core-pro-
moter/precore regions were found in patients coin-
fected with HBV and HDV but not in patients
infected with only HBV; this finding suggests that
HDV selects HBV variants with low replicative
capacity.
With regards to the control and management of
HDV infection in populations, the importance of
consistently testing for HDV cannot be understated.
Due to the complex and changing epidemiology,
inconsistent and sporadic testing may lead to under-
estimation of HDV prevalence. A report by Xiridou
et al. [2009] proposes a mathematical model in which
HBV control was studied using prevalence rates of
HDV and HBV. It was demonstrated that HDV
presence could potentially hamper HBV eradication—
and ignoring HDV infection may produce overoptimis-
tic estimates of HBV control. The study proposes
systematic HDV testing in HBV monitoring to more
effectively control HBV. While this may be open for
debate, consistent HDV testing for selected HBsAg
positive patients in higher HBV prevalence areas, and
for patients using a combination of parameters that
include low HBV DNA, detectable levels of HBsAg,
elevated ALT values, or liver fibrosis, is in line with
published guidelines [Lok and McMahon, 2009]. Fur-
thermore, a recent study by Schaper et al. [2010]
elucidates the complex HDV virology throughout its
infective course, and supports longitudinal testing as
opposed to sporadic testing of HDV viremia.
In conclusion, the study provided epidemiological
data on the prevalence of HBV–HDV coinfection in
Belgium, which is estimated to be from 3.7% to 5.5%
(29/785–44/800). However, the relatively small sam-
ple size and the cross-sectional nature of the HDV
registry did not permit an analysis of the treatment
modalities of HBV–HDV coinfection.
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